These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6989546)

  • 1. Disposition of captopril in normal subjects.
    Kripalani KJ; McKinstry DN; Singhvi SM; Willard DA; Vukovich RA; Migdalof BH
    Clin Pharmacol Ther; 1980 May; 27(5):636-41. PubMed ID: 6989546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Captopril kinetics.
    Duchin KL; Singhvi SM; Willard DA; Migdalof BH; McKinstry DN
    Clin Pharmacol Ther; 1982 Apr; 31(4):452-8. PubMed ID: 7037265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of captopril in dogs and monkeys.
    Singhvi SM; Peterson AE; Ross JJ; Shaw JM; Keim GR; Migdalof BH
    J Pharm Sci; 1981 Oct; 70(10):1108-12. PubMed ID: 7028947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure.
    Onoyama K; Hirakata H; Iseki K; Fujimi S; Omae T; Kobayashi M; Kawahara Y
    Hypertension; 1981; 3(4):456-9. PubMed ID: 7030952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal handling of captopril: effect of probenecid.
    Sinhvi SM; Duchin KL; Willard DA; McKinstry DN; Migdalof BH
    Clin Pharmacol Ther; 1982 Aug; 32(2):182-9. PubMed ID: 7047044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Captopril: pharmacology, metabolism and disposition.
    Migdalof BH; Antonaccio MJ; McKinstry DN; Singhvi SM; Lan SJ; Egli P; Kripalani KJ
    Drug Metab Rev; 1984; 15(4):841-69. PubMed ID: 6437780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the bioavailability of captopril in healthy subjects.
    Singhvi SM; McKinstry DN; Shaw JM; Willard DA; Migdalof BH
    J Clin Pharmacol; 1982; 22(2-3):135-40. PubMed ID: 7040498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Captopril kinetics in chronic congestive heart failure.
    Cody RJ; Schaer GL; Covit AB; Pondolfino K; Williams G
    Clin Pharmacol Ther; 1982 Dec; 32(6):721-6. PubMed ID: 6754211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and metabolism of the novel antihypertensive agent alacepril in rats.
    Matsumoto K; Miyazaki H; Fujii T; Yoshida K; Amejima H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):40-6. PubMed ID: 3513776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of captopril and its disulphide in biological fluids.
    Matsuki Y; Ito T; Fukuhara K; Nakamura T; Kimura M; Ono H
    J Chromatogr; 1982 Apr; 239():585-94. PubMed ID: 7047545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of probenecid on the disposition of captopril and captopril dimer in the rat.
    Drummer OH; Thompson J; Hooper R; Jarrott B
    Biochem Pharmacol; 1985 Sep; 34(18):3347-51. PubMed ID: 2994681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states.
    Onoyama K; Hirakata H; Tsuruda H; Ohchi N; Tomooka S; Motomura K; Omae T; Hayashi K; Fujishima M
    Clin Pharmacol Ther; 1985 Oct; 38(4):462-8. PubMed ID: 3899460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous captopril in healthy men.
    Creasey WA; Morrison RA; Singhvi SM; Willard DA
    Eur J Clin Pharmacol; 1988; 35(4):367-70. PubMed ID: 3058486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat.
    Drummer OH; Jarrott B
    Biochem Pharmacol; 1984 Nov; 33(22):3567-71. PubMed ID: 6095854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats.
    Matsumoto K; Nambu K; Fujii T; Takeyama K; Miyazaki H; Hashimoto M
    Arzneimittelforschung; 1986; 36(1):52-4. PubMed ID: 3006711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients.
    Giudicelli JF; Chaignon M; Richer C; Giroux B; Guedon J
    Br J Clin Pharmacol; 1984 Nov; 18(5):749-58. PubMed ID: 6095887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of renal insufficiency on the pharmacokinetics of captopril and converting enzyme inhibition in the hypertensive patient].
    Richer C; Chaignon M; Giroux B; Guédon J; Giudicelli JF
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1216-9. PubMed ID: 6098233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of captopril bioavailability by concomitant food and antacid intake.
    Mäntylä R; Männistö PT; Vuorela A; Sundberg S; Ottoila P
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):626-9. PubMed ID: 6389377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of captopril-L-cysteine, a captopril metabolite, in rats and dogs.
    Kripalani KJ; Dean AV; Migdalof BH
    Xenobiotica; 1983 Dec; 13(12):701-5. PubMed ID: 6372264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.